Dosage and usage of Lusutrombopag

Lusutrombopag is a thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic liver disease, particularly those scheduled to undergo medical or dental surgery. Thrombocytopenia often increases the risk of bleeding complications during surgery, so using Rutrombopag can help increase platelet counts, thereby reducing the risk of bleeding and ensuring smooth operation.

The usage and dosage of Rutrombopag are very important, and patients need to take it strictly in accordance with the doctor's instructions. According to current treatment guidelines, the recommended dose of Rutrombopag is 3 mg orally once daily for 7 days. Patients should begin taking the medication 8 to 14 days before scheduled surgery and ensure treatment is received 2 to 8 days after the last dose. This means that in the period before surgery, Rutrombopag can effectively increase the patient's platelet count to prevent bleeding during surgery.

Rutrombopag can be taken with or without food, so the patient's dietary schedule does not affect the effectiveness of the drug. During the medication process, if the patient misses a dose, he or she should take it as soon as possible on the same day and resume the normal medication schedule the next day. It should be noted that the use of Rutrombopag is limited to a 7-day continuous dosing regimen, and this regimen is only suitable for patients with chronic liver disease, and the purpose of the treatment is to temporarily increase platelet levels in response to upcoming surgery, rather than for long-term normalization of platelet levels.

Before taking Rutrombopag, patients need to have their platelet count tested. Doctors will usually check the platelet count no more than 2 days before surgery to make sure the patient's platelet levels are low enough to benefit from medication. During the treatment process, doctors will also conduct necessary monitoring based on the patient's specific situation to ensure that the increase in platelet levels is in line with expectations and to avoid excessive platelet counts.

Reference materials:https://www.drugs.com/mulpleta.html